Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436061 | 0.85 | MMP2 (0.41) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13436083 | 0.85 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13436064 | 0.84 | MMP2 (0.35) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13696040 | 0.83 | CHRNB2 (0.47) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13461937 | 0.81 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27740704 | 0.77 | MMP2 (0.42) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13436087 | 0.76 | MEN1 (0.34) | MMP2ANPEP | |
| SCHEMBL31664520 | 0.75 | MEN1 (0.39) | MMP2ANPEP | |
| SCHEMBL30278791 | 0.75 | MEN1 (0.39) | MMP2ANPEP | |
| SCHEMBL22821458 | 0.75 | MMP2 (0.39) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2007025949-A1 | NOVEL CYCLOALKANE CARBOXAMIDES AS FACTOR XA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049587-A1 | Factor Xa inhibitors | F12, F11, F10 | MMP2 209/4885ANPEP 223/4885CHRNB2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.